©Viva Biotech (Shanghai) Ltd. 沪ICP备12042930号   Powerd by 

Company News
【R.S.V.P.】Viva Biotech 2021 Partnership Summit
A Cradle for Promising Biotech Companies from around the World
Viva Biotech Awarded "Best Small and Medium Market Value Company"
The cradle for promising biotechnology startups all around the world.
QureBio’s Q-1802 Clinical Application Accepted by NMPA
The first Claudin 18.2/PD-L1 bispecific antibody drug accepted by NMPA.
Viva Biotech and Shanghai Biomedical Fund Announce the Cooperation to Jointly Build the Medical Innovation Achievement Transformation Platform
Viva Biotech will give full play to its capabilities and advantages as a one-stop comprehensive service platform for drug R&D.
Viva Biotech and AlphaMa Reached Cooperation Agreement on IntelligentDEL (iDEL) Screening Platform
Viva Biotech will cooperate with AlphaMa to provide clients AI-based DNA coding compound library screening technology.
Page up